Abstract
Chronic hepatitis B virus (HBV) carriers are facing the risk of progression to liver fibrosis, liver cirrhosis, and hepatocellular carcinoma. However, due to low risk, slow disease progression, and unsatisfactory short-term effect of antiviral treatment, controversy still exists over whether such patients should be given antiviral treatment. This article reviews the research advances in the necessity and feasibility of antiviral therapy for chronic hepatitis B virus carriers, so as to provide a reference for clinical practice.